Vous êtes ici

MPX Bioceutical Corporation

Liste d'échange: 
CSE
Statut: 
Delisted
Industrie: 
Diversified Industries
Symbole: 
MPX
Indice CSE: 
Devise: 

MPX Bioceutical Corporation (formerly known as The Canadian Bioceutical Corporation) is a multi-state diversified cannabis company with operations focused in the U.S. in the adult use and medical cannabis markets. The issuer’s foundation is built on its profitable operations in Arizona, with two Health 4 Life Dispensaries and well established Melting Point Extracts (MPX) Brand and GreenMart which holds  cultivation  and production licenses for both the medical and “adult use” sectors in Nevada and is already selling wholesale into the Nevada medical cannabis market. The business has also  optioned  suitable locations and intends to enter  the higher -margin retail arena by applying for at least two dispensary licenses in the Las Vegas market which will operate under the “Health for Life” brand. MPX is currently building-out facilities in Fall River,  Massachusetts, which  includes a 40,000 square foot property zoned and licensed for cannabis cultivation and a retail dispensary.  MPX  also manages and has options to purchase three dispensaries and one production facility in Maryland  .   MPX  plans to replicate its success in Arizona to become a dominant multi-state operator.

Vous êtes ici

MPX Bioceutical Corporation (MPX)

SEDAR Information

Information d'entreprise

Addresse
Yonge Norton Centre
5255 Yonge Street, Suite 701
Toronto, ON M2N 6P4
Canada
Téléphone
416-840-3725
Fax
877-595-1828
Courriel
info@mpxbioceutical.com
URL
http://www.mpxbioceutical.com
Date d’inscription à la cote
Vendredi, janvier 27, 2017
Agent de transfert
Computershare Investor Services Inc.
Vérificateur
Deloitte LLP

Capitalisation

Capitalisation: 
404014987
Réservé à l'émission: 
249197277

Company Officers

W. Scott Boyes, Chairman, President and Chief Executive Officer
Elizabeth M. Stavola, Chief Operating Officer
David McLaren, Chief Financial Officer

Bulletins

06/02/2019

2019-0215 - Retrait - MPX Bioceutical Corporation (MPX)

Le 6 février/February 2019

Following the completion of the Arrangement as set out in the Company's management information circular (the "Circular") dated December 11, 2018 and approved by the Company's security holders at the Company's special meeting held on January 15, 2019 (the "Special Meeting"), the common shares of MPX Bioceutical Corporation will be delisted at the market close today February 6, 2019.